Long‐term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis
Carlo Merkel, Renato Marin, David Sacerdoti, Carlo Donada, Giorgio Cavallarin, Pierluigi Torboli, Piero Amodio, Giuliana Sebastianelli, Massimo Bolognesi, Martina Felder, Cesare Mazzaro, Angelo Gatta – 30 December 2003 – It is clearly established that β‐blockers decrease the risk of a first variceal bleeding in cirrhosis. We have recently shown that the addition of isosorbide mononitrate to nadolol decreases the rate of variceal bleeding in patients with cirrhosis and varices, compared with nadolol alone, after a median follow‐up of 30 months.